| Expression pattern: |
UP |
| Associated gene: |
CHTOP |
| Associated microRNA: |
miR-338-3p |
| Biological function: |
Promotes DDP resistance and malignant behaviors (proliferation, cell cycle progression, migration, invasion) and inhibits apoptosis in DDP-resistant ovarian cancer cells; promotes tumor growth in vivo. |
| Molecular mechanism: |
ceRNA mechanism: circHIPK2 sponges miR-338-3p to relieve repression of CHTOP. |
| Biological pathway or process: |
chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); cell cycle (promotes); migration (promotes); invasion (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Transfection; CCK8; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; Western Blot; Luciferase Reporter Assay; RNA Pull-Down; In Vivo Animal Model |
| Clinical significance: |
circHIPK2 high expression was correlated with clinicopathological characteristics, such as tumor size, lymph node metastasis, and advanced FIGO stage. |
| Description: |
circHIPK2 is up-regulated in DDP-resistant ovarian cancer tissues and cells and promotes cisplatin resistance and malignant phenotypes. It acts as a ceRNA by sponging miR-338-3p to increase CHTOP expression, thereby enhancing proliferation/cell-cycle progression, migration/invasion and reducing apoptosis; silencing circHIPK2 suppresses tumor growth in xenografts. |
| Confidence score: |
0.7983 |